In lung cancer, the analyzed SNPs were previously investigated mainly in the context of response to targeted treatment with EGFR TKIs or, in colorectal and head and neck cancer, to treatment with anti-EGFR mAbs such as cetuximab [29,30,31,32]. Here, EGFR is linked to lung carcinoma.